Biotech companies today tend to develop intellectual property and then license or sell it, rather than focusing on an end-stage commercial product. IPOs and venture capital funding for early-stage research have declined in recent years, but pharmaceutical companies increasingly are buying small biotechs' early-stage work to supplement their own pipelines. This analysis looks at the overlay between drug development and the financial life cycle of a biotech firm.

Related Summaries